Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe
25-Feb-2015
- Sweden
“We are pleased that the European Commission have granted the Orphan Drug Designation. We are confident that our subsidiary IBT can significantly contribute in the care of premature infants in the future”, says Peter Rothschild, CEO, BioGaia.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.